These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 34505954)
41. Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome-the initial report from the Magmaris-ACS registry. Wlodarczak A; Lanocha M; Jastrzebski A; Pecherzewski M; Szudrowicz M; Jastrzebski W; Nawrot J; Lesiak M Catheter Cardiovasc Interv; 2019 Apr; 93(5):E287-E292. PubMed ID: 30537203 [TBL] [Abstract][Full Text] [Related]
42. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. von Birgelen C; Kok MM; van der Heijden LC; Danse PW; Schotborgh CE; Scholte M; Gin RMTJ; Somi S; van Houwelingen KG; Stoel MG; de Man FHAF; Louwerenburg JHW; Hartmann M; Zocca P; Linssen GCM; van der Palen J; Doggen CJM; Löwik MM Lancet; 2016 Nov; 388(10060):2607-2617. PubMed ID: 27806902 [TBL] [Abstract][Full Text] [Related]
43. Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent: Insights From the DESSOLVE III All-Comers Randomized Trial. Takahashi K; Serruys PW; Kogame N; Buszman P; Lurz P; Jessurun GAJ; Koch KT; Troquay RPT; Hamer BJB; Oude Ophuis T; Milewski KP; Hofma SH; Wykrzykowska JJ; Onuma Y; de Winter RJ; Wijns W Circ Cardiovasc Interv; 2020 Jun; 13(6):e008737. PubMed ID: 32466676 [TBL] [Abstract][Full Text] [Related]
47. Impact of Coronary Calcification on Clinical Outcomes After Implantation of Newer-Generation Drug-Eluting Stents. Hemetsberger R; Abdelghani M; Toelg R; Mankerious N; Allali A; Garcia-Garcia HM; Windecker S; Lefèvre T; Saito S; Slagboom T; Kandzari D; Koolen J; Waksman R; Richardt G J Am Heart Assoc; 2021 Jun; 10(12):e019815. PubMed ID: 34056911 [TBL] [Abstract][Full Text] [Related]
48. Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial. Xu B; Zhang YJ; Sun ZW; Qiao SB; Chen SL; Zhang RY; Pan DR; Pang S; Zhang Q; Xu L; Yang YJ; Leon MB; Gao RL Int J Cardiovasc Imaging; 2015 Dec; 31(8):1489-96. PubMed ID: 26208685 [TBL] [Abstract][Full Text] [Related]
49. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661 [TBL] [Abstract][Full Text] [Related]
50. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent). Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236 [TBL] [Abstract][Full Text] [Related]
52. Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents. Rola P; Włodarczak A; Barycki M; Szudrowicz M; Łanocha M; Kulczycki JJ; Turkiewicz K; Woźnica K; Lesiak M; Doroszko A J Diabetes Res; 2021; 2021():8636050. PubMed ID: 34859105 [TBL] [Abstract][Full Text] [Related]
53. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial. Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147 [TBL] [Abstract][Full Text] [Related]
54. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial. Orvin K; Carrie D; Richardt G; Desmet W; Assali A; Werner G; Ikari Y; Fujii K; Goicolea J; Dangoisse V; Manari A; Saito S; Wijns W; Kornowski R Catheter Cardiovasc Interv; 2016 May; 87(6):1092-100. PubMed ID: 26268482 [TBL] [Abstract][Full Text] [Related]
55. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries). Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443 [TBL] [Abstract][Full Text] [Related]